Reference : Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-I...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/19997
Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women
English
Alexandersen, P. [> > > >]
Karsdal, M. A. [> > > >]
Qvist, P. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Christiansen, C. [> > > >]
Jan-2007
BONE
Elsevier Science Inc
40
1
218-222
Yes (verified by ORBi)
International
8756-3282
New York
[en] strontium ranelate ; postmenopausal women ; CTX-II ; type II collagen degradation ; RCT
[en] Objective: Strontium ranelate significantly decreases the risk of osteoporotic fractures. The objective of the present study was to investigate whether strontium ranclate (2 g/day) also affects cartilage brakedown as measured by urinary marker of cartilage degradation, designated CTX-II. Methods: A subgroup of 2617 postmenopausal osteoporotic women (aged 75.7 +/- 4.4 years) were selected from the TROPOS phase III study on the basis of a urinary sampling reported at each visit during the first three years of the study. When included in TROPOS, they were randomized to strontium ranelate or placebo in a double-blind fashion for 3 years. A calcium and vitamin D supplement was also provided to the subjects during the study. A marker of collagen type II degradation (CTX-II) corrected for urinary creatinine (CTX-II/cr.) was assessed at regular intervals throughout the study in 1310 patients in strontium ranelate group and 1307 patients in placebo group. Results: The response in CTX-II depended on time (p < 0.0001), and this time dependency differed statistically significantly between groups (time x treatment) (p < 0.0003). In addition, there was a statistically significant difference between treatments (p < 0.0001). The difference in the response of CTX-II/cr. appeared already after three months, with the strontium ranelate-treated subjects having approximately 15-20% lower values than the placebo-treated subjects for the remaining study period (p < 0.0001). Conclusion: Treatment with strontium ranelate significantly decreases urinary excretion of CTX-II, a marker of cartilage destruction. Further studies are warranted to investigate an effect on cartilage formation and symptoms of osteoarthritis. (c) 2006 Elsevier Inc. All rights reserved.
http://hdl.handle.net/2268/19997
10.1016/j.bone.2006.07.028

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
str rane red.pdfNo commentaryPublisher postprint186.28 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.